2[3]Kume H, Kondo M, Ito Y, et al. Effects of Sustained - release Tulobuterol On Asthma Control and Beta - adrenoceptor Function [ J ]. Clin Exp Pharmacol Physiol, 2002, 29(12): 1 076 - 1 083.
4[5]Nakano Yoshihisa, Horiuchi Tetsuo, Fujivvara Sanae, et al. Percutaneous Preparation of Tulobuterol: US, 5571530[ P] 1996 - 11 - 05.
5[6]Hans R, Hoffmann, Michael Horstmann. Transdermal Therapeutic System Comprising Tulobuterol as Active Substance: US, 5254348 [ P ] 1993 - 10 -19.
6[7]OtsukaSaburo, Nakagawa Takeaki, NakanoYoshihisa. Percutaneous Tulobuterol Preparation and Process for Producing The Same: W O, 9714411 [ P]1997 - 04 - 24.
7[9]Otsuka Saburo, Hori Mitsuhiko. Percutaneous Aborption Type Preparation Containing Tulobuterol: EP, 0922453 [ P ] 1999 - 06 - 16.
9Wang SZ,Smith PK,Lovejoy M,et al.The apoptosis of neutrophils is accelerated in respiratory syncytial virus(RSV)-induced bronchiolitis[J].Clin Exp Immunol,1998,114(1):49-54.
10Bont L,Kavelaars A,Heijnen CJ,et al.Monocyte interleukin-12 production is inversely related to duration of respiratory failure in respiratory syncytial virus bronchiolitis[J].J Infect Dis,2000,181(5):1772-1775.
6Hozawa S, Haruta Y,Terada M,et al. Effects of the addition of Beta2- agonist tulobuterol patches to inhaled corticosteroid in patients with asthma[J]. Allergol Inter,2009,58(4) :509-518.
